Leonard Zehr, Author at BioTuesdays

Features

Soricimed’s platform of unique peptides making waves in cancer and beyond

Closely-held Soricimed Biopharma has developed a first-in-class platform of synthetic peptides whose various targets include an “oncochannel” implicated in the development and progression of many forms of cancer.

October 29, 2019

Features

Salarius Pharmaceuticals targeting epigenetic causes of cancers

David Arthur, President and CEO Salarius Pharmaceuticals (NASDAQ:SLRX) is poised to ride the growing epigenetic wave with a differentiated lead drug candidate, seclidemstat, in early clinical development for the...

October 22, 2019

Features

KemPharm sees license deal, debt restructuring as transformative events

KemPharm (NASDAQ:KMPH) hit a home run last month when it inked a transformative licensing deal of up to $493-million with an affiliate of Gurnet Point Capital, a private equity firm focused on the life science sector...

October 15, 2019

Features

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

Daniel O’Connor, President and CEO OncoSec Medical (NASDAQ:ONCS) is developing its TAVO drug candidate to enhance local delivery and uptake of DNA-based interleukin-12 (IL-12) directly into solid tumors to reverse...

October 8, 2019

Features

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

Sebastian Hadjiantoniou As a co-founder and CEO of closely-held Incuvers, an early-stage life sciences company developing a sophisticated incubator for cellular biologists, Sebastian Hadjiantoniou knows firsthand the...

October 1, 2019

Features

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

Dr. RJ Tesi, CEO and CMO INmune Bio (NASDAQ:INMB) is developing new therapies that modulate the innate immune system, the body’s first line of defense against pathogens, to treat cancer and neuroinflammation that lead...

September 24, 2019

Developments

XORTX reports positive Phase 2 results in Type 2 diabetic nephropathy

XORTX Therapeutics (CSE:XRX; OTCQB:XRTXF), in conjunction with partner, Teijin Pharma, posted positive, statistically significant results with its TMX-049 drug candidate in a U.S. Phase 2 clinical trial in individuals...

September 20, 2019

Features

CytoDyn developing leronlimab (PRO140) as a pipeline in a drug

CytoDyn (OTCQB:CYDY), which is in the process of filing for FDA approval for leronlimab (PRO140) in treatment-experienced HIV patients, is continuing to develop its lead drug candidate in eight metastatic solid tumors...

September 17, 2019

Features

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

DelMar Pharmaceuticals (NASDAQ:DMPI) is conducting two Phase 2 clinical trials with its lead drug candidate, VAL-083, a DNA-targeting agent, in three distinct biomarker-driven glioblastoma multiforme (GMB) patient...

September 10, 2019

Features

Precipio aims to prevent misdiagnosis of blood-related cancers

Using a combination of advanced lab technologies, and a platform giving access to expert academic pathologists, Precipio (NASDAQ:PRPO) has staked out a unique position in its battle to prevent misdiagnosis of blood...

August 27, 2019

Author - Leonard Zehr

Soricimed’s platform of unique peptides making waves in cancer and beyond

Salarius Pharmaceuticals targeting epigenetic causes of cancers

KemPharm sees license deal, debt restructuring as transformative events

OncoSec TAVO technology aiming to reverse checkpoint inhibitor resistance

Sebastian Hadjiantoniou of Incuvers discusses accelerating cellular research

INmune Bio harnessing innate immune system against cancer, neurodegenerative diseases

XORTX reports positive Phase 2 results in Type 2 diabetic nephropathy

CytoDyn developing leronlimab (PRO140) as a pipeline in a drug

DelMar Pharma developing VAL-083 in biomarker-driven GBM patient populations

Precipio aims to prevent misdiagnosis of blood-related cancers

Follow Us

Subscribe

General

More

Subscribe